Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+, HER2- metastatic breast cancer, node positive, and early breast cancer. It offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis. The company offers Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Its Bamlanivimab and etesevimab, and Bebtelovimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. The company has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; Regor Therapeutics Group; Lycia Therapeutics, Inc.; Kumquat Biosciences Inc.; Entos Pharmaceuticals Inc.; and Foghorn Therapeutics Inc. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.

Mr. Jeffrey N. Simmons

Senior Vice President & President of Elanco Animal Health

Ms. Anat  Hakim J.D.

Executive Vice President, General Counsel & Secretary

Mr. Diogo  Rau

EVice President & Chief Information and Digital Officer

Mr. David A. Ricks

Chairman, Chief Executive Officer & President

Mr. Donald A. Zakrowski

Senior Vice President of Finance & Chief Accounting Officer

Dr. Daniel M. Skovronsky M.D., Ph.D.

EVice President, Chief Scientific Officer and President of Lilly Research Laboratories & Lilly immunology

Mr. Jacob S. Van Naarden

Executive Vice President & President of Loxo

Mr. Alonzo  Weems

EVice President of Enterprise Risk Management and Chief Ethics & Compliance Officer

Mr. Eric  Dozier

Executive Vice President of Human Resources & Diversity

Ms. Anat  Ashkenazi

Executive Vice President & Chief Financial Officer

Name	Marktkapitalisierung
Marksans Pharma Limited	0M
Luye Pharma Group Ltd.	0M
PT Kalbe Farma Tbk.	0M
Virbac SA	0M
Daiichi Sankyo Company, Limited	0M
Astellas Pharma Inc.	0M
NGL Fine-Chem Limited	0M
Bristol-Myers Squibb Company	0M
Orion Oyj	0M
Chugai Pharmaceutical Co., Ltd.	0M
Novartis AG	0M

Eli Lilly and Company

Eli Lilly and Company Liste der Konkurrenten

Wichtigste Wettbewerber